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Background: Renal cell carcinoma, a common malignant tumor arising from the kidney, occurs in 3.62 and 1.95
cases per one hundred thousand people among men and women, respectively, in Taiwan each year. Approximately
80% of cases are classified as clear-cell renal cell carcinoma. Inactivation of the von Hippel-Lindau tumor suppressor
gene has been implicated in the tumorigenic pathway of renal cell carcinoma. Two single nucleotide polymorphisms,
rs779805 and rs1642742, located in the promoter and 3′ untranslated regions of the von Hippel-Lindau gene are
informative and implicated in the occurrence of renal cell carcinoma worldwide. The aim of this study is to clarify
whether these polymorphisms are associated with renal cell carcinoma in Taiwanese. Genomic DNA was isolated from
normal and tumor tissues of 19 renal cell carcinoma patients. The samples were screened for allelic polymorphisms by
restriction fragment length polymorphism with BsaJ I and Acc I digestion. Reconfirmation was carried out by direct
sequencing.
Results: Consistent with Knudson’s two-hit theory, AA to AG somatic mutations were observed in rs779805. In addition,
loss of heterozygosity in both rs779805 and rs1642742 was demonstrated in 10 out of 15 RCC patients aged 50 or over.
The G allele or AG heterozygote frequencies at these two loci were much higher in patient germline DNA when
compared with the control group. After adjusting for age, the frequency of the G allele in both loci was much
higher for late onset renal cell carcinoma in the Taiwanese population.
Conclusions: Our current results confirmed that the existence of G allele in both rs779805 and rs1642742 in the
von Hippel-Lindau tumor suppressor gene is of importance in renal cell carcinoma tumorigenesis. However, more
comprehensive and detailed research is needed to address the clinical relevance. Larger sample size is required to
determine the exact power of correlation between these two genetic polymorphisms and renal cell carcinoma.
Keywords: Loss of heterozygosity, Renal cell carcinoma, Single nucleotide polymorphism, Von Hippel-Lindau
tumor suppressor geneBackground
Von Hippel-Lindau (VHL) disease (OMIM 193300) is an
autosomal dominantly inherited tumor syndrome affecting
1 in 36,000 in the human population [1]. The most com-
mon types of tumors are retinal angioma, cerebellar and
spinal hemangioblastoma, clear cell renal cell carcinoma
(RCC) and pheochromocytoma [2]. Tumors form when
there is biallelic VHL tumor suppressor gene inactivation* Correspondence: yenchein@csmu.edu.tw
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unless otherwise statedin a two hit model of tumorigenesis [3-5]. The VHL
tumor suppressor gene is located on the short arm of
chromosome 3 mapped to 3p25-3p26 and consists of
639 nucleotides in 3 exons encoding 213 amino acids
[6,7]. Germ-line mutations have been detected in approxi-
mately 500 VHL family members including deletions in
part of or the whole gene, as well as intragenic point
mutations and micro-deletions/insertions [8]. Somatic
inactivating mutations have been identified in tumors
from VHL-affected [9] and sporadic RCC [6,10] patients.
The etiology of renal cancer is still not fully understood.
Nevertheless, a number of environmental factors have
been implicated in sporadic RCC [11]. RCC is the mosttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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per 100,000 people, which is equal to about 3% of all
adult cancers in Western countries [12]. Most RCCs
are classified as clear-cell RCC. More than half of RCC
cases are linked to either VHL gene mutations or tran-
scriptional repression with hypermethylation in the
promoter and first exon regions [13,14]. Multiple and
bilateral RCCs are present in up to 40% of VHL patients.
It is highly possible that subjects with VHL disease will de-
velop RCC if they live long enough [15]. As early detection
and intervention have reduced the death rate from VHL
central nervous complications, bilateral multiple cystic
RCC has become the leading cause of death in patients
with VHL disease [16]. Recent reports have shown that
acquired cystic disease-associated RCC frequently occurs
with abnormalities on chromosome 3 in the Taiwanese
population [17]. To date, no studies have focused on the
association between VHL gene malfunction and RCC in
Taiwan.
Two single nucleotide polymorphisms (SNPs), rs779805
and rs1642742 involving both A and G, located in the pro-
moter and 3′ untranslated regions of the VHL gene are
informative and implicated in the occurrence of RCC
worldwide [18-20]. The aim of this study is to clarify
whether these polymorphisms are associated with RCC in
Taiwanese. We confirmed somatic mutation and loss of
heterozygosity (LOH) at these two loci in RCC patients. In
addition, a genetic association pilot study using these two
SNPs for germline DNA genotyping was conducted to test
the potential causality between VHL gene dysfunction and
RCC susceptibility in the Taiwanese population.Methods
Study subjects
Paraffin-embedded normal and tumor tissue samples from
RCC patients were provided by the Tumor Tissue Bank of
the Koo Foundation Sun Yat-Sen Cancer Center, which is
funded by the National Science and Technology Program
for Pharmaceuticals and Biotechnology (#NSC89-2323-B-
368-001). The control group consisted of 616 unrelated
individuals and has been described in our previous report
[21]. DNA sample collection for the VHL SNP study
protocol was approved by the Institutional Review Board
of Chung Shan Medical University Hospital and informed
consent was obtained from each subject.Preparation of Genomic DNA
The tissues were deparaffinized using standard xylene-
deparaffin procedure. Genomic DNA was isolated from
normal and tumor tissues using QIAamp DNA kit
(Qiagen). The concentration of nucleic acids was estimated
by GeneQuant II RNA/DNA calculator (Amersham
Pharmacia Biotech). Each genomic DNA sample wasadjusted to 100 ng/ml and served as a template for
subsequent analyses.
Polymerase chain reaction (PCR)
VHL rs779805A > G and rs1642742A > G were detected
on polymerase chain reaction–restriction fragment length
polymorphism (PCR-RFLP) assays according to the
methods described by Gail et al. and Payne et al.
[22,23]. Slight modifications were made in the PCR primers




ACTGAATTACGTATA-3′. PCR fragments were ampli-
fied in a Perkin-Elmer 2400 DNA thermal cycler in a final
volume of 15 to 30 μl that contained one-fold Qiagen
PCR buffer [Tris–HCl, KCl, (NH4)2SO4, 15 mM MgCl2;
pH 8.7 at 20°C], one-fold Q-solution, 0.015 units/μl Taq
DNA polymerase supplied from Taq DNA polymerase kit
(Qiagen), 500 nM for each primer, 200 mM dGTP, dATP,
dCTP and dTTP (Promega) and 300 ng/μl template. PCR
conditions included initial denaturation for 5 min at 95°C,
followed by 35 cycles consisting of 1 min at 95°C, 1 min at
60°C for rs779805 or 50°C for rs1642742, and 2 min at
72°C, with final extension for 10 min at 72°C.
Digestion of restriction enzyme
An aliquot of 10 μl of PCR product was digested with
2.5 units BsaJ I (New England Biolabs) for rs779805 or
2.5 units Acc I (New England Biolabs) for rs1642742 in a
total volume of 20 μl that contained one-fold NEBuffer 2
or NEBuffer 4. The samples were digested at 60°C for
rs779805 or 37°C for rs1642742 for 4 hrs followed by
heat inactivation of the restriction enzyme at 80°C for
20 min. After digestion, the products were separated onto
3% agarose gels. To avoid genotyping errors, analysis was
repeated at least twice for each sample. Portions of the
PCR products were sent for direct sequencing and the
data were consistent with the genotyping.
Direct sequencing
The A/G polymorphisms at nucleotides 19 (rs779805) and
1149 (rs1642742) in the VHL gene were analyzed by PCR
amplification using published primers and experimental
protocols [8,20,24]. The PCR products were purified using
QIAquick PCR Purification kits (Qiagen). Then, the
purified PCR products were sequenced by the cycle-
sequencing method with fluorescently labeled dideoxy
chain terminators from ABI Prism kit (Applied Biosys-
tems) in an ABI Model 377 automated DNA sequencer.
The sequencing primers were the same as those for the
preceding PCRs. The nucleotide sequence was confirmed
on both strands.
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Standard normal deviate (z) test or chi-square test was
used to compare the genotype and allelic frequencies be-
tween the control and patient groups. p values of less than
0.05 were considered statistically significant and p values
of less than 0.01 were considered highly significant.
Results
Somatic changes in rs779805 and rs1642742 in the VHL
gene in RCC patients
We compared the DNA from normal and tumor tissues
from RCC patients to investigate somatic gene alteration.
We observed AA to AG somatic mutations in four RCC
cases, aged 50 or over, among a total 12 AA homozygotes
(33.3%) at rs779805 (Table 1). All four RCC cases with AA
homozygote at rs779805 were aged less than 50 and pos-
sessed the same genotype in their tumor tissues. Similar
phenomena were not observed for rs1642742.
In addition to AA to AG somatic mutations, LOH was
identified in RCC patients with AG heterozygote at
rs779805 and rs1642742. PCR-RFLP analysis of hetero-
zygotes of A allele and G allele normally results in two
equal bands. However, there were differences between
normal and tumor tissues (Additional file 1: Figure S1).Table 1 RCC patients with and without somatic mutations of
# Age Gender Stage Clear ce
With somatic mutations
1 66 Female III Yes
2 77 Female I Yes
3 50 Male I Yes
4 53 Female II Yes
5 83 Female I Yes
6 51 Male I Yes
7 70 Female IV# Yes
8 51 Male III Yes
9 53 Female I Yes
10 63 Female II Yes
Without somatic mutations
11 67 Male I Yes
12 62 Male III Yes
13 45 Male I Yes
14 72 Female II Yes
15 31 Male I Yes
16 33 Male I Yes
17 40 Female I Yes
18 70 Male I Yes
19 76 Male I No
#metastasis; *ND, no somatic changes were detected.We compared the relative extent of these two bands
from tumor tissue with that from normal tissue and
obtained a ratio (R). LOH was considered positive
when R was larger than 1.25 or smaller than 0.8. There
were seven AG heterozygotes at rs779805 (out of 19 RCC
cases). Five of them (71.4%) showed LOH (Table 1). In
addition to digestion of restriction enzyme, we further
confirmed LOH by DNA sequencing and the sequencing
patterns were significantly altered at rs779805 (Figure 1),
with three demonstrating G alleles (Figure 1A, C, E). In
addition, there were eight AG heterozygotes at rs1642742
with six (75.0%) showing LOH (Table 1). Four of them
possessed G alleles (Figure 2C, D) and the remaining two
possessed A alleles (Figure 2C). There were seven AG
heterozygotes at rs779805. These seven individuals also
demonstrated AG heterozygote at rs1642742. Four out of
these seven (57.1%) showed LOH in both loci. All RCC
patients with LOH were aged 50 or over.
Consistent with Knudson’s two-hit theory, AA to AG
somatic mutations were present in rs779805 and LOH
was present in both rs779805 and rs1642742 in 10 out
of 15 RCC patients aged 50 or over (Table 1). To test
whether these polymorphisms are associated with predis-
position for RCC in Taiwanese, a genetic association pilotrs779805 and rs1642742 of VHL gene in tumor tissue
rs779805 rs1642742
lls Normal Tumor Normal Tumor
AG LOH (G) AG LOH (G)
AG LOH (A) AG LOH (A)
AG LOH (G) AG LOH (G)
AG LOH (A) AG ND*
AG ND* AG LOH (G)
AG LOH (G) AG LOH (A)
AA AG AG LOH (G)
AA AG AA ND*
AA AG AA ND*
AA AG AA ND*
AG ND* AG ND*
AA ND* AA ND*
AA ND* AA ND*
AA ND* AA ND*
AA ND* AA ND*
AA ND* AA ND*
AA ND* AA ND*
AA ND* AA ND*
AA ND* AA ND*
Figure 1 Partial sequencing chromatograms of the VHL gene containing rs779805 in reverse direction from tumor tissues. The rs779805
is represented by a rectangular frame. (A), (C), and (E) represent examples of loss of heterozygosity (LOH) of the A allele at rs779805 of VHL gene
in RCC patients (#1, #3, and #6 in Table 1). (B) and (D) represent loss of the G allele (#2 and #4). (F) is a heterozygote with two almost equal
bands (#11).
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DNA genotyping.
AG heterozygote frequencies in both rs779805 and
rs1642742 increase in the germline DNA of RCC patients
We have previously reported that the G allelic frequencies
in both rs779805 and rs1642742 of VHL gene in
healthy subjects from Taiwan are much lower than in
the European population [21]. Here, we examined the
genotype distributions and G allelic frequencies at
these two SNPs in normal tissues, which represented
germline DNA, of RCC patients from Taiwan. In normal
control subjects (n = 616), the frequencies of the G allele
at rs779805 and rs1642742 were 0.130 and 0.133, respect-
ively, whereas in RCC patients (n = 19) the frequencies of
the G allele at rs779805 and rs1642742 were 0.184 and
0.211, respectively (Table 2). The G allelic frequenciesincreased 41.5% (0.184/0.130) and 58.6% (0.211/0.133),
respectively, in RCC patients. In normal control sub-
jects, the observed heterozygosities for rs779805 and
rs1642742 were 0.214 and 0.218, respectively, whereas
in RCC patients the observed heterozygosities for
rs779805 and rs1642742 were 0.368 and 0.421, respect-
ively (Table 2). The frequencies of heterozygous genotype
increased 71.9% (0.368/0.214) and 93.1% (0.421/0.218),
respectively, in RCC patients. Similar phenomena were
observed when we compared frequencies of the G allele
carriage (AG +GG), with increases from control level of
0.237 to 0.368 for rs779805 (55.3% increase) and from
0.242 to 0.421 for rs1642742 (74.0% increase).
A positive correlation between RCC and G variant has
been indicated [21], suggesting that the G variant is a
lethal genetic mutation resulting in the lack of GG
homozygote in the RCC patients in the current study.
Figure 2 Partial sequencing chromatograms of the VHL gene containing rs1642742 in reverse direction. The rs1642742 is represented by
a rectangular frame. Normal tissue (A) and tumor tissue (B) from heterozygous individual #1 in Table 1 show LOH. (B) and (D) represent examples of
LOH of the A allele at rs1642742 of VHL gene in the tumor tissues from RCC patients (#1 and #7). (C) represents loss of the G allele (#2).
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quency increases, chance of somatic changes and sus-
ceptibility to RCC increase. However, further studies
with a larger sample size are needed to verify this
hypothesis.Table 2 Comparison of the frequency distributions of rs77980




AA 12 (63.16%) 470
AG 7 (36.84%) 132
GG 0 14
Allele frequency
A allele 31 (81.58%) 107
G allele 7 (18.42%) 160
Homozygous genotype
(AA or GG genotype) 12 (63.16%) 484
Heterozygous genotype
(AG genotype) 7 (36.84%) 132
Allele carriage frequency
A allele (AA+AG) 19 (100%) 602
G allele (AG+GG) 7 (36.84%) 146
#Data presented as number of cases and percentage; bold text means statistical sig
RCC patients and controls.Patient characteristics in relation to rs779805 and
rs1642742 genotypes in patients with RCC
The main characteristics of the patient population are
shown in Table 3. Age (≥50, <50), sex, clear cell type
(yes/no), and tumor stage (early, stage I; late, stage II to5 and rs1642742 of VHL gene in the germline DNA of
rs1642742
controls# 19 RCCs# 616 controls#
(76.30%) 11 (57.89%) 467 (75.81%)
(21.43%) 8 (42.10%) 134 (21.75%)
(2.27%) 0 15 (2.44%)
2 (87.01%) 30 (78.95%) 1068 (86.69%)
(12.99%) 8 (21.05%) 164 (13.31%)
(78.57%) 11 (57.89%) 482 (78.25%)
(21.43%) 8 (42.01%) 134 (21.75%)
(97.73%) 19 (100%) 601 (97.56%)
(23.70%) 8 (42.10%) 149 (24.19%)
nificance was reached, p < 0.05, in the comparison of germline DNA between
Table 3 Analysis of patient characteristics in relation to rs779805 and rs1642742 genotypes in patients with RCC
rs779805 rs1642742
All patients# AA genotype# AG genotype# AA genotype# AG genotype#
Total 19 12 (63.16%) 7 (36.84%) 11 (57.89%) 8 (42.10%)
Age
<50 years 4 4 (100%) 0 (0%) 4 (100%) 0 (0%)
≥50 years 15 8 (53.33%) 7 (46.67%) 7 (46.67%) 8 (53.33%)
Gender
Male 10 7 (70.00%) 3 (30.00%) 7 (70.00%) 3 (30.00%)
Female 9 5 (50.00%) 4 (40.00%) 4 (40.00%) 5 (50.00%)
Tumor stage
I 12 7 (58.33%) 5 (41.67%) 7 (58.33%) 5 (41.67%)
II+III+IV 7 5 (71.43%) 2 (28.57%) 4 (57.14%) 3 (42.86%)
Clear cells
No 1 1 (100%) 0 (0%) 1 (100%) 0 (0%)
Yes 18 11 (61.11%) 7 (38.89%) 10 (55.56%) 8 (44.44%)
#Data presented as number of cases and percentage; bold text means statistical significance was reached, p < 0.05, in the comparison of genotype distributions
between two sub-groups.
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[25]. Delayed onset is a key feature of sporadic cancers.
On multivariate analysis, age was an important factor in
the genotype distributions of both rs779805 and rs1642742
(Table 3). For all RCC patients, the observed frequencies of
heterozygosity for rs779805 and rs1642742 were 0.368 and
0.421, respectively. In all four RCC cases aged less than 50,
AA homozygote was observed at both rs779805 and
rs1642742. Among the 15 RCC cases aged 50 or over, the
observed frequencies of heterozygosity for rs779805 and
rs1642742 were 0.467 and 0.533, respectively. The fre-
quencies of heterozygous genotype increased 26.9%
(0.467/0.368) and 26.6% (0.533/0.421), respectively, in
RCC patients aged 50 or over. These data suggested that
the frequencies of AG heterozygote at both rs779805
and rs1642742 in the VHL tumor suppressor gene are
much higher for late onset RCC in the Taiwanese popula-
tion. Somatic changes in rs779805 and rs1642742 were
only observed in RCC patients aged 50 or over (Table 1).
Adjustment for tumor stage (I vs II + III + IV) did not
significantly affect the genotype distributions (Table 3).
Gender and clear cell type were factors in the genotype
distributions of both rs779805 and rs1642742 (Table 3).
Among female RCC cases, the frequencies of heterozy-
gous genotype increased from 0.368 for total patients
to 0.400 for rs779805 (8.7% increase) and from 0.421
for total patients to 0.500 for rs1642742 (18.8% in-
crease). Among clear cell RCC cases, the frequencies
of heterozygous genotype increased from 0.368 for
total patients to 0.389 for rs779805 (5.7% increase) and
from 0.421 for total patients to 0.444 for rs1642742
(5.4% increase).Discussion
All increases in rs1642742 shown in Table 2 and Table 3
are higher than in rs779805, indicating that rs1642742 is
a more sensitive risk factor for sporadic RCC. However,
further studies with a larger sample size are needed to
clarify this phenomenon. Statistical significance was
reached with just 19 samples for AG heterozygote fre-
quencies in rs1642742 in the comparison of germline
DNA between RCC patients and controls using chi-square
test (χ2 = 4.397, p = 0.036; bold in Table 2). Statistical signifi-
cance was also reached in both loci between older and total
RCC cases (χ2 = 5.132, p = 0.023* for rs779805; χ2 = 7.948,
p = 0.0048* for rs1642742; bold in Table 3). AG heterozy-
gote at rs1642742 was significantly associated with female
gender and clear cell type (p = 0.018* and p = 0.028*; bold
in Table 3). However, the small sample size of 19 pa-
tients in this study may not be enough to make broad
generalizations.
Among the RCC patients in this study, the G allele
carriage in rs779805 showed a slightly increasing trend.
The location of rs779805 is 128 bp upstream from the
major transcription-starting site within the promoter
region of the VHL gene and its 5’ adjacent nucleotide is
C. The somatic mutations from AA homozygote to AG
heterozygote at rs779805 create a new CpG island that
can be methylated to suppress gene expression. A similar
rationale can be applied to RCC patients with germline
AG heterozygote at rs779805. These somatic mutations
were observed in four out of 15 RCC patients aged 50 or
over (Table 1). The accumulation of somatic mutations
becomes more evident late in life. Cancer may develop
after shutting down of the function of VHL gene, when A
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the CpG island.
Among the haploinsufficient tumor suppressor genes,
it is possible that one allele is not able to function suffi-
ciently [26]. Previous evidence regarding the Dmp1 gene
has shown the effect of haploinsufficiency on tumorigen-
esis [27]. The differences in the distributions of AA homo-
zygote and AG heterozygote at rs779805 and rs1642742 in
this study may be a case of haploinsufficiency. GG homo-
zygote was not observed in our RCC samples. A possible
explanation is that GG homozygote causes early cell death
before clinical cancer can develop.
Our results were consistent with those of previous
reports, namely that VHL gene dysfunction is observed
in sporadic RCC, as well as in hereditary cases [13,28,29].
Three polymorphic markers at 3p25-p26 have been exam-
ined for LOH in RCC [18]. Patients with sporadic RCC
have been shown to have LOH in two SNPs in VHL gene
[19,20] and present with a biallelic polymorphism with
either an A or a G at positions 19 (rs779805) and 1149
(rs1642742) in the nucleotide sequence [22,23]. From a
series of studies performed in Western countries, the G
allele carriage at rs779805 and rs1642742 is an important
risk factor for clear cell RCC [25], consistent with our
findings. In this study, it was found that LOH at rs779805
and rs1642742 in the VHL gene in RCC patients manifests
only late in life (Table 1). Our results were also consistent
with previous findings of LOH in most RCC patients with
AG heterozygosity [19,20]. The current findings agree
with Knudson’s two-hit theory that, in addition to gene
mutation and hypermethylation, LOH is one of the major
mechanisms resulting in tumor suppressor gene (such as
VHL gene) inactivation [3-5]. LOH in tumor suppressor
gene has been observed in most populations. However,
ethnic differences may affect the frequency of occurrence
[30]. LOH was considered positive when R was larger than
1.25 or smaller than 0.8 because even partial inactivation
of tumor suppressors can contribute to tumorigenesis [5].
Linehan et al. reported that VHL gene inactivation
might occur in the early stage of tumorigenesis in RCC
[31]. In this study, most RCC patients with AG hetero-
zygosity were identified as having LOH. LOH in VHL
gene, therefore, is a beneficial tool for early diagnosis of
RCC, as well as for monitoring of recurrence in RCC
patients [31]. VHL gene polymorphism/association in-
formation obtained from this study is useful for further
genetic RCC studies and for facilitating the development
of new treatments. The results of this study can also be
used to establish genetic diversity panels for the VHL
tumor suppressor gene in the local population. Although
further studies with larger sample sizes are needed to
address the details of the association of VHL SNPs
with RCC, as well as ethnic variation, these SNPs may
be useful genetic tumor markers for the moleculardiagnostics of clear cell RCC in the elderly population
in Taiwan.
Conclusions
In the current study, we examined the association of two
allelic VHL gene polymorphisms, rs779805 and rs1642742,
with RCC in patients from Taiwan. By comparing the DNA
from normal and tumor tissues, AA to AG somatic mu-
tations at rs779805 and loss of heterozygosity at both
rs779805 and rs1642742 in 10 out of 15 RCC patients
aged 50 or over were observed. In comparison with the
healthy control group, the G allele and AG heterozygote
frequencies at these two loci were much higher in the
patient germline DNA than in the control group on
genetic association pilot study, especially for rs1642742
and late onset RCC, suggesting that the existence of G
allele at both rs779805 and rs1642742 is of importance
in RCC tumorigenesis. However, more comprehensive
and detailed research is needed to address the clinical
relevance. Larger sample size is required to determine the
exact power of correlation between these two genetic
polymorphisms and RCC.
Additional file
Additional file 1: Figure S1. RFLP analysis was used to screen for the
allele genotype of rs779805 by BsaJ I digestion methods. Examples of
rs779805 identified in three RCC patients. Lanes 1, 3, and 5 are normal
tissues; Lanes 2, 4, and 6 are tumor tissues. The upper band represents
A allele in uncleaved 101-bp PCR fragments. The lower band represents
G allele with cleavage of 101-bp PCR fragments into fragments of
83-bp and 18-bp in length. The 18-bp fragments were run off
the gel.
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